PsilodexMedication × psilocybin
Your list , 0 items
Medication class

Antipsychotics and psilocybin.

39 records in this group. 4 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.

39Records
4With human data

Overview

Reviewed 2026-10-25

Most antipsychotics block 5-HT2A, the serotonin receptor psilocybin acts on (Halman 2024). In small controlled studies in healthy volunteers, risperidone weakened psilocybin's effects in a dose-dependent way, and chlorpromazine reduced pupil dilation and visual distortion (Vollenweider 1998; Keeler 1967). Haloperidol, which mainly blocks dopamine D2 receptors, did not prevent psilocybin's effects: it reduced some, left visual effects unchanged and increased anxiety (Vollenweider 1998). Most other antipsychotics, including quetiapine and aripiprazole, have not been studied with psilocybin.

Stopping a maintenance antipsychotic, especially abruptly, is linked to a higher risk of relapse (Viguera 1997).

Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Rule 2.2(A)(7) lists conditions under which they may, and rule 2.5(A)(2) covers Clinical Facilitators (4 CCR 755-1); the rule text does not state how 2.2(A)(6) and (7) fit together. The rule does not define “antipsychotic medications”, so whether it covers amoxapine, promethazine products or metoclopramide is unsettled; those records sit in other classes and show Colorado as Unsettled. No Oregon provision names the class, and New Mexico's rules are not final.

Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.

Also searched as antipsychotic · neuroleptic

01 What the evidence covers

Best evidence available per medication
3Controlled trial
1Other psychedelic
Human data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text
35No psilocybin data
No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Each medication

A to Z
  • Amisulpride · Solian, BarhemsysEvidence: No psilocybin data

    Postoperative nausea and vomiting (prevention and treatment)

    This antipsychotic barely acts at the receptor psilocybin works through, so weakening of psilocybin is uncertain. Stopping it suddenly after regular use can cause relapse.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Aripiprazole · Abilify, Abilify Maintena, Aristada, Abilify Asimtufii, OpipzaEvidence: No psilocybin data

    Schizophrenia; Bipolar I disorder (manic and mixed episodes)

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Asenapine · Saphris, SecuadoEvidence: No psilocybin data

    Schizophrenia; Bipolar I disorder (manic or mixed episodes, alone or with lithium or valproate, and maintenance)

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Blonanserin · LonasenEvidence: No psilocybin data

    Psychotropics

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Brexpiprazole · RexultiEvidence: No psilocybin data

    Major depressive disorder (add-on to antidepressants); Schizophrenia

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Cariprazine · VraylarEvidence: No psilocybin data

    Schizophrenia; Bipolar I disorder (manic or mixed episodes)

    It also blocks the receptor psilocybin works through, though more weakly, so it may weaken psilocybin's effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Chlorpromazine · ThorazineEvidence: Controlled trial

    Schizophrenia and other psychotic disorders; Mania in bipolar disorder

    In a small study, 50 mg given 2 hours earlier reduced psilocybin's pupil dilation and visual distortion. Also, it sedates and can lower blood pressure.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Clozapine · Clozaril, VersaclozEvidence: No psilocybin data

    Treatment-resistant schizophrenia; Reducing suicidal behavior in schizophrenia or schizoaffective disorder

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can cause low blood pressure, sedation and seizures.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Cyamemazine · TercianEvidence: No psilocybin data

    Psychotropics

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it is sedating and can affect heart rhythm.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Flupenthixol · Fluanxol, DepixolEvidence: No psilocybin data

    Psychotropics

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • FluphenazineEvidence: No psilocybin data

    Psychotic disorders; Schizophrenia requiring long-term injectable treatment (decanoate)

    Not studied with psilocybin. In a small study, haloperidol, a similar dopamine blocker, did not prevent psilocybin's effects but increased anxiety.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Haloperidol · HaldolEvidence: Controlled trial

    Psychotic disorders; Tourette's disorder (tics)

    In a controlled study, it reduced psilocybin's sense of boundlessness and detachment but increased anxiety; visual effects were unchanged.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Iloperidone · FanaptEvidence: No psilocybin data

    Schizophrenia in adults; Manic or mixed episodes of bipolar I disorder in adults

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Stopping it suddenly after regular use can cause relapse.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Loxapine · Loxitane, AdasuveEvidence: No psilocybin data

    Schizophrenia; Agitation in schizophrenia or bipolar I disorder (inhaled form, adults)

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can make seizures more likely.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Lumateperone · CaplytaEvidence: No psilocybin data

    Schizophrenia; Bipolar depression (bipolar I or II)

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Lurasidone · LatudaEvidence: No psilocybin data

    Schizophrenia; Bipolar depression (bipolar I)

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Milsaperidone · BysantiEvidence: No psilocybin data

    Schizophrenia in adults; Manic or mixed episodes of bipolar I disorder in adults

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Stopping it suddenly after regular use can cause relapse.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • MolindoneEvidence: No psilocybin data

    Schizophrenia

    A related drug did not block psilocybin's effects in a small study but raised anxiety; molindone is expected to act similarly.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Olanzapine · ZyprexaEvidence: No psilocybin data

    Schizophrenia; Bipolar I disorder (manic or mixed episodes and maintenance)

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can lower blood pressure on standing.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Olanzapine–fluoxetine · SymbyaxEvidence: Other psychedelic

    Bipolar depression (bipolar I); Treatment-resistant depression

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Olanzapine–samidorphan · LybalviEvidence: No psilocybin data

    Schizophrenia; Bipolar I disorder (manic or mixed episodes and maintenance)

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can trigger severe opioid withdrawal.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Paliperidone · Invega, Invega Sustenna, Invega Trinza, Invega Hafyera, ErzofriEvidence: No psilocybin data

    Schizophrenia; Schizoaffective disorder

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, injected forms last for months.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Perospirone · LullanEvidence: No psilocybin data

    Psychotropics

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Stopping it suddenly after regular use can cause relapse.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • PerphenazineEvidence: No psilocybin data

    Schizophrenia; Severe nausea and vomiting (adults)

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, the combination product with amitriptyline adds that antidepressant's effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Pimavanserin · NuplazidEvidence: No psilocybin data

    Hallucinations and delusions in Parkinson's disease psychosis

    It directly blocks the receptor psilocybin works through, so it is expected to cancel psilocybin's effects. Also, it can cause heart-rhythm (QT) effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Pimozide · OrapEvidence: No psilocybin data

    Motor and vocal tics of Tourette's disorder (after standard treatment)

    Not studied with psilocybin; haloperidol, a similar dopamine blocker, did not prevent psilocybin's effects but increased anxiety. Also, pimozide can affect heart rhythm (QT).

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Pipothiazine palmitate · PiportilEvidence: No psilocybin data

    Psychotropics

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, the injection stays in the body for weeks.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Prochlorperazine · CompazineEvidence: No psilocybin data

    Severe nausea and vomiting; Schizophrenia

    Whether it weakens psilocybin's effects is uncertain; a similar dopamine blocker, haloperidol, increased anxiety with psilocybin. Also, it is sedating.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Quetiapine · Seroquel, Seroquel XREvidence: No psilocybin data

    Schizophrenia; Bipolar I disorder (manic episodes)

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Stopping it suddenly after regular use can cause withdrawal.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Risperidone · Risperdal, Risperdal Consta, Perseris, Uzedy, RykindoEvidence: Controlled trial

    Schizophrenia; Bipolar I disorder (acute manic or mixed episodes)

    In a controlled study, it weakened psilocybin's effects, more at the higher dose. Also, long-acting injections keep it in the body.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Sertindole · SerdolectEvidence: No psilocybin data

    Psychotropics

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can cause marked heart-rhythm (QT) effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Sulpiride · DolmatilEvidence: No psilocybin data

    Psychotropics

    It mainly blocks dopamine, not psilocybin's receptor, so any weakening of psilocybin is possible but unstudied. Also, it can affect heart rhythm and seizure risk.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Thioridazine · MellarilEvidence: No psilocybin data

    Schizophrenia not responding to other antipsychotics

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it strongly affects heart rhythm (boxed warning).

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Thiothixene · NavaneEvidence: No psilocybin data

    Schizophrenia

    Whether it weakens psilocybin is uncertain; a related drug, haloperidol, increased anxiety with psilocybin. Also, it causes sedation and low blood pressure.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • TrifluoperazineEvidence: No psilocybin data

    Schizophrenia; Generalized anxiety (short-term, non-psychotic)

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can cause low blood pressure and sedation.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Xanomeline–trospium · CobenfyEvidence: No psilocybin data

    Schizophrenia (adults)

    It does not block psilocybin's receptor, and its effect on psilocybin is unknown. Also, it often causes nausea, vomiting and faster heart rate.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Ziprasidone · GeodonEvidence: No psilocybin data

    Schizophrenia; Bipolar I disorder (manic or mixed episodes and maintenance)

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can affect heart rhythm and cause sleepiness.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Zotepine · ZoleptilEvidence: No psilocybin data

    Psychotropics

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can cause sleepiness and affect heart rhythm.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Zuclopenthixol · Clopixol, Clopixol Acuphase, Clopixol DepotEvidence: No psilocybin data

    Psychotropics

    Its serotonin-blocking action may weaken psilocybin. Also, it can affect heart rhythm and cause sedation; the depot injection persists for weeks.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

03 Properties the records flag

Records with each flag
33Lowers blood pressure or causes orthostasis
33Sedating or CNS depressant
32Lowers seizure threshold or carries seizure risk
31Blocks 5-HT2A (may blunt effects)
21QT-prolonging
16Anticholinergic
16Withdrawal or rebound if stopped abruptly
7Psychiatric reactions
1Dehydration or electrolyte risk
1Opioid blocker
1Raises blood pressure or heart rate
1Serotonergic

Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.

04 State rules

Official text governs
COColorado · final · checked 2026-10-24

39 of 39 named by a provision.

Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” and does not limit this by indication or dose. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).

Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” and does not limit this by indication or dose; prochlorperazine is a phenothiazine antipsychotic FDA-approved for schizophrenia as well as severe nausea and vomiting. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).

Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” without defining the term or limiting it by indication, so it is shown here as covering this medication; the regulator has not addressed this. Xanomeline–trospium is FDA-approved for schizophrenia, but it acts on muscarinic receptors and does not block dopamine receptors, the action other antipsychotics share. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).

OROregon · final · checked 2026-10-24

No provision names these medications or this group.

NMNew Mexico · pending · checked 2026-10-24

Rules not final; the proposed rules reviewed name no medication in this group.

05 Studies cited in this group

Records citing each
38Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
36Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 1998;9:3897–3902.
6Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997;54(1):49–55.
1Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996;14:425–436.
1Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008;22(6):603–620.
1Keeler MH. Chlorpromazine antagonism of psilocybin effect. Int J Neuropsychiatry 1967;3:66–71.
1Ochi T, Sakamoto M, Minamida A, et al. Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423. Bioorg Med Chem Lett 2005;15:1055.
1Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.

Records reviewed 2026-10-14 to 2026-11-02. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z

AgreementPsilodex

Before you use Psilodex

Check each box to continue.

Your searches, your list and the medications you look up stay in this browser. We can't see them. Privacy · Emergency: 911 · Mental health crisis: call or text 988 · Poison Control: 1-800-222-1222

Terms version 2026-10-25